drug
lifitegrast
Marketedupdated 5mo agoby $BLCO Bausch & Lomb Corp
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lifitegrast
- phase4A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
- phase2A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- phase4This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye
- —Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
- phase3A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
- phase1Lifitegrast Eye Drops in Healthy Subjects：Phase I Study
- phase2A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
- phase2A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 15, 2029
~2.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Dec 18, 2033formulationUS 11058677
- Jul 25, 2033formulationUS 9085553
- Nov 12, 2030formulationUS 89275744.1y
- Oct 21, 2030formulationUS 93530884.0y
- Oct 21, 2030compositionUS 98901414.0y
- May 9, 2029method-of-use (U-1880)US 81686552.6y
- Apr 15, 2029formulationUS 83677012.5y
- Apr 15, 2029method-of-use (U-1900)US 94470772.5y
- May 17, 2026compositionUS 8084047
- May 17, 2026method-of-use (U-1880)US 8592450
News(2)
- Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trialA real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.biopharma_dive · 1mo ago
- Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage failWhile Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.biospace · 1mo ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that